By PPN News Staff
The FDA approved a bivalent RSV prefusion F vaccine (RSVpreF; Abrysvo, Pfizer) to prevent lower respiratory tract disease caused by respiratory syncytial virus in people 60 years of age and older.
RSVpreF is unadjuvanted and composed of two preF proteins selected to optimize protection against RSV A and B strains, and was observed to be safe and effective.